Beyond-use window: reconstituted solution has a limited stable life (commonly a few weeks refrigerated)
High-risk groups who should be considered for monitoring include: Patients taking metformin for more than three years Those on high-dose metformin (2g daily) Older adults (aged 65 years and above), who have reduced gastric acid production and lower B12 stores Patients with pre-existing risk factors for B12 deficiency, including previous gastric surgery, pernicious anaemia, or inflammatory bowel disease Individuals following vegan or vegetarian diets with limited dietary B12 intake Those taking acid-suppressing medications (proton pump inhibitors or H2-receptor antagonists) Patients with symptoms suggestive of B12 deficiency Patients with unexplained anaemia or neuropathy The frequency of monitoring should be guided by clinical judgement and local pathways, with consideration of individual risk factors

Code History FY 2026 - No Change, effective from 10/1/2025 through 9/30/2026 FY 2025 - No Change, effective from 10/1/2024 through 9/30/2025 FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024 FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023 FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022 FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021 FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020 FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019 FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018 FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017 FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
"However, dont expect miracles